# Pizarra — PT-pseudo_2fbb84505a45 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2fbb84505a45
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 8.4 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 2.3 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 78.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.44532543 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.4 ng/mL. PI-RADS 4. PSAD 0.10. Prostate volume 78 mL. csPCa 0.45.

Vitals: weight 65 kg, height 176 cm, BMI 21.0, BP 135/64 mmHg, HR 73 bpm. Smoking: Ex-smoker (27 pack-yr, quit 2011).

Chief complaint: Persistent PSA elevation and prior positive prostate biopsy warrant clinical reassessment.

History: A 63-year-old graphic designer, married and residing with his partner, initially presented for evaluation of a PSA elevation detected in early 2024. Lower urinary tract symptoms remain mild, scoring an IPSS of 5 without significant daily disruption. Physical activity continues at a steady pace, featuring two weekly cycling sessions covering roughly 20 kilometres each, alongside complete abstinence from alcohol. Surgical past history includes a resolved childhood appendectomy and a minor arthroscopic knee intervention in 2018. Tobacco use ceased entirely in 2011, following a cumulative 27 pack-year exposure. The patient reports no unexplained weight fluctuations, skeletal discomfort, or haematuria.

Physical examination: DRE — texture: smooth and rubbery; symmetry: intact; nodularity: absent. The prostate demonstrates uniform enlargement. Vital parameters remain stable, recording a blood pressure of 135/64 mmHg and a regular pulse of 73 bpm. Abdominal and cardiovascular assessments yield no abnormalities, while peripheral lymph nodes and bony structures show no tenderness or enlargement.

Patient info: graphic designer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 2x/week, ~20 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.19   (95% CI 0.14-0.86)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 7.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=8.4, age=63.0, psad=0.1, dre_ord=0.0, vol=78.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (2.3 ng/mL/yr) against the prior PSA (6.7 ng/mL), which suggests a significant recent rise, and the specific details within the mpMRI report (PI-RADS 4) that are not fully captured by the score alone. It also missed the context provided by the previous positive biopsy status, which fundamentally changes the interpretation of the current findings.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.50 +/- 0.19). This wide interval indicates the classifier is highly uncertain. A failure mode is that the prior ignores the high PSA velocity (2.3 ng/mL/yr) and the prior positive biopsy result, which strongly argue for further investigation, potentially pushing the decision towards 'YES'. Another failure mode is that the prior treats the PI-RADS 4 score in isolation, failing to integrate it with the clinical context of a prior positive biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features, it would increase the likelihood of biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the likelihood of biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain clinical context regarding the persistent elevation and the rationale for the current re-evaluation.
  <document> laboratory results (full panel) -> This panel might provide context on other markers that influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_2fbb84505a45", "radiology_report": "Subject: Multiparametric MRI Prostate | Amsterdam UMC (VUmc) | 15 Feb 2025\nClinical context: Rising PSA (8.4 ng/mL) alongside a previously positive biopsy, raising suspicion for prostate malignancy.\n\nFINDINGS:\nProstatic parenchyma spans 78.0 mL. A distinct hypointense focus occupies the right mid-gland peripheral zone, measuring roughly 12 by 9 mm. Restricted diffusion characterizes this area on DWI, mirrored by attenuated signal on the ADC map. Early focal enhancement appears on dynamic contrast sequences compared to adjacent tissue. Seminal vesicles maintain normal morphology. No evidence of extracapsular extension or suspicious lymph nodes.\n\nIMPRESSION:\n1. PI-RADS 4 lesion situated in the right mid-gland peripheral zone.\n2. Prostate volume 78.0 mL, yielding a PSA density of 0.1 ng/mL/mL.\ncsPCa predicted probability 0.44532543"}
  
  **psa_trend**
  {"case_id": "PT-pseudo_2fbb84505a45", "psa_trend": [{"date": "Mar 2024", "val": 2.1}, {"date": "Jul 2024", "val": 3.0}, {"date": "Oct 2024", "val": 2.2}, {"date": "Feb 2025", "val": 8.4}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_2fbb84505a45", "previous_notes": [{"date": "29 Oct 2024", "author": "Dr. K. Bakker (GP)", "text": "The patient underwent clinical review on 29 October 2024 after PSA levels increased to 6.7 ng/mL, a jump from the 4.0 ng/mL recorded in July. A transrectal ultrasound-guided biopsy was subsequently performed, returning a positive result for low-grade adenocarcinoma (Gleason 3+3)."}]}
  
  **lab_results**
  {"case_id": "PT-pseudo_2fbb84505a45", "laboratory_results": [{"name": "PSA", "val": "8.4 ng/mL", "date": "18 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.62 ng/mL", "date": "18 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "19%", "date": "18 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.9 g/dL", "date": "18 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.8 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "214 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "85 umol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.6 nmol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "LDH", "val": "173 U/L", "date": "18 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity: 2.3 ng/mL/yr (from initial prompt data, confirmed by trend data showing a rise to 8.4 ng/mL).
  - mpMRI finding: PI-RADS 4 lesion in the right mid-gland peripheral zone with restricted diffusion and focal enhancement.
  - Prior positive biopsy result: Positive result for low-grade adenocarcinoma (Gleason 3+3) from Oct 2024.
  - PSA trend: Significant rise from 6.7 ng/mL (Oct 2024) to 8.4 ng/mL (Feb 2025).
  
  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - csPCa predicted probability: 0.44532543 (clinically significant PCa = ISUP ≥ 2).

WHERE THIS LEANS
  The retrieved evidence strongly argues for further investigation due to the combination of a high-risk MRI finding (PI-RADS 4), a concerning PSA velocity, and a history of a prior positive biopsy. This leans towards recommending biopsy to further characterize the lesion identified on MRI.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports further investigation due to the combination of a high-risk MRI finding (PI-RADS 4 lesion) and a concerning PSA velocity of 2.3 ng/mL/yr. This is further supported by the patient's history of a prior positive biopsy for low-grade adenocarcinoma. The PSA trend shows a significant rise from 6.7 ng/mL to 8.4 ng/mL, which, combined with the high PI-RADS score, warrants sampling to characterize the identified lesion.

Variables that carried weight: bx=important, psa=decisive, psad=noted, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
